Age-related differences in factors associated with the underuse of recommended medications in acute coronary syndrome patients at least one year after hospital discharge

BMC Cardiovascular Disorders

Naifeng Liu¹  Genshan Ma¹  Qin Sun¹  Long Chen¹  Qin Wei¹  Chengchun Tang¹  Hong Jin¹ 

[1] Department of Cardiology, Zhongda Hospital, Medical School of Southeast University, 210009 Nanjing, Jiangsu, China

关键词: Coronary heart disease;    Aged;    Age factors;    Secondary prevention;    Medications;   

Others  :  1088445
DOI  :  10.1186/1471-2261-14-127

 received in 2013-11-25, accepted in 2014-09-19,  发布年份 2014

【 摘 要 】

Background

Few studies have evaluated age-related predictors associated with the underuse of medications in patients with coronary heart disease (CHD). The objective of this study was to identify age-related differences in the factors associated with the underuse of recommended medications in patients diagnosed with acute coronary syndrome (ACS).

Methods

From August 2009 to April 2011, we recruited 469 consecutive ACS patients from a cardiac center at a university hospital. We divided the patients into older (65 years of age and older, n = 202) and younger groups (younger than 65 years of age, n = 267). Data on socio-demographic characteristics, depressive symptoms, and medication use were obtained from a telephone survey administered 18 to 24 months after hospital discharge. Additionally, we asked the patients to provide reasons for not taking their medications.

Results

A significantly increased underuse of medication was noted in older patients compared with younger patients, including aspirin (24.8% vs. 37.1%, p = 0.005), beta-blockers (20.3% vs. 34.8%, p = 0.001), ACE inhibitor/angiotensin receptor blockers (27.2% vs. 36.7%, p = 0.030), and statins (21.8% vs. 29.6%, p = 0.005). Among older patients, the factors associated with the underuse of medications included low education level (odds ratio [OR], 3.93), greater number of comorbidities (OR, 1.64), and total number of discharge medications (OR, 1.31). The reasons provided by older patients for not taking medication included the fact that the medication was considered to be non-essential and the large number of medications. Among younger patients, low income (OR, 3.97) and depression (OR, 2.62) were predictors for underuse of medication, and the reasons provided for not taking medications included high costs and the fear of adverse effects.

Conclusions

At least one year after ACS hospital discharge, the underuse of recommended medications is related to low education level, comorbidities, and the total number of discharge medications in elderly patients, whereas underuse in younger patients is associated with low income and depression. The disparities related to these different predictors may have implications for age-related interventions targeting secondary preventions in CHD patients to improve their use of medication.

【 授权许可】

   
2014 Jin et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Zhang XH, Lu ZL, Liu L: Coronary heart disease in China. Heart 2008, 94(9):1126-1131.
• [2]Critchley J, Liu J, Zhao D, Wei W, Capewell S: Explaining the increase in coronary heart disease mortality in Beijing between 1984 and 1999. Circulation 2004, 110(10):1236-1244.
• [3]Niu S, Zhao D, Zhu J, Liu J, Liu Q, Liu J, Wang W, Smith SC Jr: The association between socioeconomic status of high-risk patients with coronary heart disease and the treatment rates of evidence-based medicine for coronary heart disease secondary prevention in China: Results from the Bridging the Gap on CHD Secondary Prevention in China (BRIG) Project. Am Heart J 2009, 157(4):709-715. e1
• [4]Yang Z, Olomu A, Corser W, Rovner DR, Holmes-Rovner M: Outpatient medication use and health outcomes in post-acute coronary syndrome patients. Am J Manag Care 2006, 12(10):581-587.
• [5]Setoguchi S, Glynn RJ, Avorn J, Mittleman MA, Levin R, Winkelmayer WC: Improvements in long-term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge: a 10-year trend analysis. J Am Coll Cardiol 2008, 51(13):1247-1254.
• [6]Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pearson T, Pfeffer MA, Taubert KA: AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol 2006, 47(10):2130-2139.
• [7]DeWilde S, Carey IM, Richards N, Whincup PH, Cook DG: Trends in secondary prevention of ischaemic heart disease in the UK 1994 2005: use of individual and combination treatment. Heart 2008, 94(1):83-88.
• [8]Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA: AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006, 113(19):2363-2372.
• [9]Ho PM, Bryson CL, Rumsfeld JS: Medication adherence: its importance in cardiovascular outcomes. Circulation 2009, 119(23):3028-3035.
• [10]Wright RS, Anderson JL, Adams CD, Bridges CR, Casey DE Jr, Ettinger SM, Fesmire FM, Ganiats TG, Jneid H, Lincoff AM, Peterson ED, Philippides GJ, Theroux P, Wenger NK, Zidar JP, Jacobs AK: 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011, 123(18):2022-2060.
• [11]Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, Bailey SR, Bates ER, Blankenship JC, Casey DE Jr, Green LA, Hochman JS, Jacobs AK, Krumholz HM, Morrison DA, Ornato JP, Pearle DL, Peterson ED, Sloan MA, Whitlow PL, Williams DO: 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009, 120(22):2271-2306.
• [12]Ho PM, Spertus JA, Masoudi FA, Reid KJ, Peterson ED, Magid DJ, Krumholz HM, Rumsfeld JS: Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med 2006, 166(17):1842-1847.
• [13]Newby LK, LaPointe NM, Chen AY, Kramer JM, Hammill BG, DeLong ER, Muhlbaier LH, Califf RM: Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 2006, 113(2):203-212.
• [14]Ho PM, Magid DJ, Shetterly SM, Olson KL, Maddox TM, Peterson PN, Masoudi FA, Rumsfeld JS: Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J 2008, 155(4):772-779.
• [15]Gislason GH, Rasmussen JN, Abildstrom SZ, Gadsboll N, Buch P, Friberg J, Rasmussen S, Kober L, Stender S, Madsen M, Torp-Pedersen C: Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J 2006, 27(10):1153-1158.
• [16]Ali RC, Melloni C, Ou FS, Schmader K, Ohman EM, Roe MT, Peterson ED, Alexander KP: Age and persistent use of cardiovascular medication after acute coronary syndrome: results from medication applied and sustained over time. J Am Geriatr Soc 2009, 57(11):1990-1996.
• [17]Lee HY, Cooke CE, Robertson TA: Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge. J Manag Care Pharm 2008, 14(3):271-280.
• [18]Kulkarni SP, Alexander KP, Lytle B, Heiss G, Peterson ED: Long-term adherence with cardiovascular drug regimens. Am Heart J 2006, 151(1):185-191.
• [19]Spitzer RL, Kroenke K, Williams JB: Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. JAMA 1999, 282(18):1737-1744.
• [20]Bi Y, Gao R, Patel A, Su S, Gao W, Hu D, Huang D, Kong L, Qi W, Wu Y, Yang Y, Turnbull F: Evidence-based medication use among Chinese patients with acute coronary syndromes at the time of hospital discharge and 1 year after hospitalization: results from the Clinical Pathways for Acute Coronary Syndromes in China (CPACS) study. Am Heart J 2009, 157(3):509-516. e1
• [21]Grines CL, Bonow RO, Casey DE Jr, Gardner TJ, Lockhart PB, Moliterno DJ, O’Gara P, Whitlow P: Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007, 115(6):813-818.
• [22]Makaryus AN, Friedman EA: Patients’ understanding of their treatment plans and diagnosis at discharge. Mayo Clin Proc 2005, 80(8):991-994.
• [23]Kripalani S, Henderson LE, Jacobson TA, Vaccarino V: Medication use among inner-city patients after hospital discharge: patient-reported barriers and solutions. Mayo Clin Proc 2008, 83(5):529-535.
• [24]Brown MT, Bussell JK: Medication adherence: WHO cares? Mayo Clin Proc 2011, 86(4):304-314.
• [25]Garner JB: Problems of nonadherence in cardiology and proposals to improve outcomes. Am J Cardiol 2010, 105(10):1495-1501.
• [26]Libby AM, Fish DN, Hosokawa PW, Linnebur SA, Metz KR, Nair KV, Saseen JJ, Vande Griend JP, Vu SP, Hirsch JD: Patient-level medication regimen complexity across populations with chronic disease. Clin Ther 2013, 35(4):385-398. e1
• [27]Mojtabai R, Olfson M: Medication costs, adherence, and health outcomes among Medicare beneficiaries. Health Aff (Millwood) 2003, 22(4):220-229.
• [28]Xu L, Wang Y, Collins CD, Tang S: Urban health insurance reform and coverage in China using data from National Health Services Surveys in 1998 and 2003. BMC Health Serv Res 2007, 7:37. BioMed Central Full Text
• [29]Fang K, Jiang Y, Shia B, Ma S: Impact of illness and medical expenditure on household consumptions: a survey in western China. PLoS One 2012, 7(12):e52928.
• [30]Jiang W, Glassman A, Krishnan R, O’Connor CM, Califf RM: Depression and ischemic heart disease: what have we learned so far and what must we do in the future? Am Heart J 2005, 150(1):54-78.
• [31]Whooley MA: Depression and cardiovascular disease: healing the broken-hearted. JAMA 2006, 295(24):2874-2881.
• [32]Gehi A, Haas D, Pipkin S, Whooley MA: Depression and medication adherence in outpatients with coronary heart disease: findings from the Heart and Soul Study. Arch Intern Med 2005, 165(21):2508-2513.
• [33]Rieckmann N, Kronish IM, Haas D, Gerin W, Chaplin WF, Burg MM, Vorchheimer D, Davidson KW: Persistent depressive symptoms lower aspirin adherence after acute coronary syndromes. Am Heart J 2006, 152(5):922-927.
• [34]Bauer LK, Caro MA, Beach SR, Mastromauro CA, Lenihan E, Januzzi JL, Huffman JC: Effects of depression and anxiety improvement on adherence to medication and health behaviors in recently hospitalized cardiac patients. Am J Cardiol 2012, 109(9):1266-1271.
• [35]Ali R, Alexander KP: Statins for the primary prevention of cardiovascular events in older adults: a review of the evidence. Am J Geriatr Pharmacother 2007, 5(1):52-63.
• [36]McGinnis B, Olson KL, Magid D, Bayliss E, Korner EJ, Brand DW, Steiner JF: Factors related to adherence to statin therapy. Ann Pharmacother 2007, 41(11):1805-1811.
• [37]Cook SC, Arnott LM, Nicholson LM, Cook LR, Sparks EA, Daniels CJ: Erectile dysfunction in men with congenital heart disease. Am J Cardiol 2008, 102(12):1728-1730.
• [38]Diaz A, Tardif JC: Heart rate slowing versus other pharmacological antianginal strategies. Adv Cardiol 2006, 43:65-78.
• [39]Gehi AK, Ali S, Na B, Whooley MA: Self-reported medication adherence and cardiovascular events in patients with stable coronary heart disease: the heart and soul study. Arch Intern Med 2007, 167(16):1798-1803.
• [40]Rashid MA, Edwards D, Walter FM, Mant J: Medication taking in coronary artery disease: a systematic review and qualitative synthesis. Ann Fam Med 2014, 12(3):224-232.
• [41]Eagle KA, Kline-Rogers E, Goodman SG, Gurfinkel EP, Avezum A, Flather MD, Granger CB, Erickson S, White K, Steg PG: Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med 2004, 117(2):73-81.
• [42]Lappe JM, Muhlestein JB, Lappe DL, Badger RS, Bair TL, Brockman R, French TK, Hofmann LC, Horne BD, Kralick-Goldberg S, Nicponski N, Orton JA, Pearson RR, Renlund DG, Rimmasch H, Roberts C, Anderson JL: Improvements in 1-year cardiovascular clinical outcomes associated with a hospital-based discharge medication program. Ann Intern Med 2004, 141(6):446-453.